Clinical Trials on Advanced NSCLC

Total 6634 results

Shenzhen People's Hospital

Unknown

To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma (RCTACSCNSCLC)

NSCLC | EGFR

China
Taiho Oncology, Inc.

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

United States, Japan, Spain, Italy, France, Australia, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
Stanford University

Terminated

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

Lung Cancer | Mesothelioma | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer Small Cell Lung Cancer (SCLC)

United States
ETOP IBCSG Partners Foundation
Takeda

Recruiting

Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer (BOUNCE)

NSCLC, Stage III | ALK-rearrangement

France, Spain, Italy, Poland, United Kingdom
IO Biotech
Merck Sharp & Dohme LLC

Completed

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

NSCLC

United Kingdom, Germany, Netherlands, Spain
Maastricht Radiation Oncology
University of Pennsylvania; University of Wisconsin, Madison

Completed

Photon Versus Particle Therapy for Recurrent Lung Cancer; a Planning Study Based on a Reference Dataset of Patients.

NSCLC

Netherlands
Fujian Cancer Hospital

Unknown

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Chemotherapy Effect | NSCLC Stage IV

China
AstraZeneca

No longer available

AZD9291 US Expanded Access Program

EGFR T790M Mutation Positive NSCLC

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Squamous NSCLC

China
Shandong Cancer Hospital and Institute

Recruiting

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Unresectable Stage III NSCLC

China
Molecular Partners AG

Terminated

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

EGFR-mutated NSCLC (Disorder)

United States
TORL Biotherapeutics, LLC
Translational Research in Oncology

Recruiting

First in Human Study of TORL-1-23 in Participants With Advanced Cancer (TRIO049)

Ovarian Cancer | NSCLC | Advanced Solid Tumor | Endometrial Cancer

United States
Xueqin Yang

Recruiting

RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC

NSCLC | Targeted Therapy | Evaluation

China
Zhejiang Cancer Hospital

Not yet recruiting

Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC (R-helper)

Unresectable Stage III NSCLC
Anhui Medical University

Unknown

Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy

NSCLC

China
Merus N.V.
Chiltern International Inc.; Q2 Solutions; Oncology Therapeutic Development (OTD) and other collaborators

Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Gastric Cancer | Colorectal Cancer | NSCLC | Head and Neck Squamous Cell Carcinoma | HNSCC | Advanced/Metastatic Solid Tumors | Gastroesophageal-junction Cancer

United States, Spain, Belgium, France, Netherlands, United Kingdom
Novartis Pharmaceuticals

Terminated

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Advanced Non Small Cell Lung Cancer (NSCLC)

France, Italy, Taiwan, Spain, Netherlands, Japan, Hong Kong, Korea, Republic of, Norway, United States, United Kingdom, Poland
European Organisation for Research and Treatment...

Not yet recruiting

Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC (ICARS)

NSCLC Stage IV
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

NSCLC Stage IV

China
NYU Langone Health

Recruiting

Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC (IRRADIATE-Lung)

NSCLC Stage IV

United States
Zhejiang Cancer Hospital

Recruiting

SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors

NSCLC Stage IV

China
IRCCS Policlinico S. Matteo

Recruiting

Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC. (DEDALUS)

NSCLC, Stage III

Italy
Institut für Klinische Krebsforschung IKF GmbH...
AstraZeneca; Thoraxklinik-Heidelberg gGmbH

Recruiting

Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (TRADE-hypo)

NSCLC, Stage III

Germany
Shanghai 10th People's Hospital

Unknown

Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLC

NSCLC and Theropy

China
The First People's Hospital of Lianyungang
Hengrui Yuanzheng Bio-Technology Co., Ltd.

Unknown

Neo-MASCT Immunotherapy for Advanced NSCLC.

NSCLC Stage IV

China
Intergroupe Francophone de Cancerologie Thoracique
Bristol-Myers Squibb; Pierre Fabre Laboratories; Ligue contre le cancer, France

Completed

Chemoradiotherapy of NSCLC Stage IIIB

NSCLC Stage IIIB | Concomitant Radiochemotherapy

France
Tianjin Chest Hospital

Recruiting

Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD

NSCLC With COPD

China
Shanghai Chest Hospital
Bristol-Myers Squibb

Completed

Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC

NSCLC Stage IV | Checkpoint Inhibitor

China
lihegen

Unknown

Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection

NSCLC
AstraZeneca

Completed

Iressa as Second Line Therapy in Advanced NSCLC-Asia (ISTANA)

NSCLC

Korea, Republic of
ETOP IBCSG Partners Foundation
AstraZeneca

Active, not recruiting

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (STEREO)

NSCLC Stage IV | EGFR Gene Mutation

Singapore, Sweden, Korea, Republic of, Spain, Switzerland, Netherlands, Italy, Poland
Pfizer

Terminated

Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors

Advanced Solid Tumors | Advanced Cancer

United States
VA Office of Research and Development
Oncovir, Inc.

Not yet recruiting

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC (HAITEN-ICI)

Stage IV NSCLC

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

NSCLC, Stage I

China
Yuan Chen

Recruiting

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

NSCLC, Stage III

China
Wuhan Union Hospital, China

Not yet recruiting

Monitoring the Efficacy of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC by Sequencing of Immune Receptor Repertoire: a Prospective, One Arm Clinical Study

Ib-IIIb NSCLC
Fudan University

Recruiting

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

NSCLC Stage IV

China
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

NSCLC Stage IV

Netherlands
Oncology Institute of Southern Switzerland
Ente Ospedaliero Cantonale, Bellinzona; Clinical Trial Unit Ente Ospedaliero... and other collaborators

Active, not recruiting

Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC

NSCLC Stage IV

Switzerland
AIO-Studien-gGmbH
AstraZeneca

Withdrawn

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

NSCLC Stage IV

Germany
Hunan Province Tumor Hospital

Completed

Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Non-squamous NSCLC

China
Amsterdam UMC, location VUmc

Unknown

Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery

NSCLC, Stage I
Institute of Cancer Research, United Kingdom

Active, not recruiting

Stereotactic Body Radiotherapy for the Treatment of OPD (HALT)

NSCLC

United Kingdom, France, Switzerland, Italy, Spain
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment (JS001)

NSCLC

China
Zivena

Unknown

Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)

NSCLC

United States
ETOP IBCSG Partners Foundation
Mirati Therapeutics Inc.

Recruiting

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status (ADEPPT)

NSCLC Stage IV | KRAS P.G12C

Ireland, Italy, France, Spain, United Kingdom, Belgium
BeiGene

Active, not recruiting

Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer, Stage IV | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)

United States, China, Korea, Republic of, France, Spain, Australia, Austria
Xiangya Hospital of Central South University

Recruiting

Efficacy and Safety of NSCLC Patients With/Without Adjuvant Immunotherapy Who Have Achieved pCR After Neoadjuvant Immunotherapy

Resectable/Potentially Resectable NSCLC

China
Tang-Du Hospital

Recruiting

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

NSCLC Stage IV | Oligometastasis

China
AstraZeneca

Completed

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

T790M Positive NSCLC Patients

China

Clinical Trials on Advanced NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations